Post Category

Microbix Expands Pandemic Test Controls (QAPs™) Portfolio

Microbix Expands Pandemic Test Controls (QAPs™) Portfolio

Helping Ensure Workflow Accuracy of PCR Tests for COVID “Variants of Concern” MISSISSAUGA, CANADA, November 17, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include controls that support PCR tests for each of the four major variants of concern (“VOCs”) of the SARS-CoV-2 virus that is the cause of the COVID-19 pandemic. Specifically, Microbix has developed, and is now commercializing, In-Vitro Diagnostic (“IVD”)...

Microbix Receives $2.7 Million from Exercise of Warrants

Microbix Receives $2.7 Million from Exercise of Warrants

Further Capital to Assist with Increasing Capacity and Efficiency MISSISSAUGA, CANADA, October 27, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has received C$ 2.7 million from the partial exercise of two series of expiring share purchase warrants. The first series of such warrants were issued in connection with a private placement undertaken in October, 2015, and had an exercise price of C$ 0.55 and a five-year term. The original term of these warrants was extended by one year, as...

Microbix Makes Early Repayment of 9% Interest Debenture

Microbix Makes Early Repayment of 9% Interest Debenture

$1.3 million balance repaid, improving cash flow and resulting in non-cash charge MISSISSAUGA, CANADA, October 4, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has completed the early repayment of a debenture series on which it owed C$ 1.3 million and was paying an interest rate of 9.0%. This debenture was issued on January 31, 2014 for an outstanding amount C$ 2.0 million and was subsequently being repaid via quarterly payments of interest and principal of $61,100. At October 1,...

Microbix Presenting Product Results at AACC

Microbix Presenting Product Results at AACC

QAPs to Support Testing for COVID Viral Variants MISSISSAUGA, CANADA, September 27, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products (QAPs™) at “AACC” the annual scientific meeting & clinical laboratory exposition of the American Association of Clinical Chemistry, taking place in live and virtual formats from Atlanta, GA, September 26-30, 2021. The abstract poster presentation is...

Microbix Poster Covering SARS-CoV-2 Variants of Concern (VOC) QAPs at AACC 2021

Microbix Presenting at Muskoka Capital Conference

Meetings with Growth-Oriented Investors, September 24-26, 2021 MISSISSAUGA, September 23, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter,  announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, ON, September 24-26, 2021. Microbix’s CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the...

Microbix Reports Record Results for Q3 Fiscal 2021

Microbix Reports Record Results for Q3 Fiscal 2021

Record Sales of $5.5 million, Record Net Earnings of $1.5 million MISSISSAUGA, August 12, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its third quarter and nine months of fiscal 2021 ending June 30, 2021 (“Q3” and “YTD”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from innovative, proprietary, and branded medical devices. Management Discussion Q3 revenues were up 88% from 2020, achieving a record level...

Microbix Receives $2.7 Million from Exercise of Warrants

Microbix Upgrades U.S. OTC Market & Investor Relations

Trading Upgrade to OTCQX Best Market and Torrey Hills Capital Engaged MISSISSAUGA, ON, August 3, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has undertaken two actions to improve its profile with United States (U.S.) based investors and to improve its trading liquidity in that market; (i) effective today, achieving qualification to trade on the OTCQX® Best Market under the symbol MBXBF, and (ii) engaged the California-based firm Torrey Hills Capital for U.S. directed investor...

Microbix Poster Covering SARS-CoV-2 Variants of Concern (VOC) QAPs at AACC 2021

Microbix Posters at 31st ECCMID 2021

Two Posters Reporting on Cross-Platform Utility of Antigen & Serological QAPs™ Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective Quality Controls Advanced SARS-CoV-2 nucleocapsid protein swab based formulation for use as cross-platform EQA sample and as a prospective Quality Control  

Microbix Presenting Product Results to Industry

Microbix Presenting Product Results to Industry

Two Abstracts Reporting on Cross-Platform Utility of Antigen & Serological QAPs™ MISSISSAUGA, CANADA, July 8, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products (QAPs™) at “ECCMID 2021” the 31st annual congress organized by the European Society of Clinical Microbiology and Infectious Diseases, taking place in virtual format July 9-12, 2021. The first abstract poster presentation is...

Microbix Makes Early Repayment of 9% Interest Debenture

Microbix Announces Quality Products Distribution Agreement

Appointment of Thomas Scientific as U.S. Distributor MISSISSAUGA, July 7, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the appointment of Thomas Scientific LLC as distributor of Microbix’s quality assessment products (QAPs™) for the United States. Under an agreement between the parties, Thomas Scientific has been appointed as the second distributor of Microbix’s QAPs in the United States. Thomas Scientific will thereby provide customer service, sales and marketing, distribution, and...

Microbix Secures Third Ontario Manufacturing Site

Microbix Secures Third Ontario Manufacturing Site

Leasing and Equipping 10,000 Square Foot Building Adjacent to Current Sites MISSISSAUGA, June 3, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has secured a third manufacturing site in Mississauga, Ontario, by way of a long-term lease agreement for a property adjacent to its two current sites. Specifically, Microbix has secured a multi-year lease to a 10,000 square foot industrial building located at 275 Watline Avenue – Immediately next to its owned biologicals facility that is...

Microbix Makes Early Repayment of 9% Interest Debenture

Microbix Announces Quality Products Distribution Agreement

Appointment of SDT Molecular of Singapore MISSISSAUGA, May 31, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the appointment of SDT Molecular Pte Ltd (SDT) as distributor of Microbix’s quality assessment products (QAPs™) for four Asia-Pacific territories. Under an agreement between the parties, SDT has been appointed as distributor of Microbix’s QAPs for Hong Kong, Indonesia, Malaysia, and its home base of Singapore. SDT will thereby provide customer service, sales and marketing,...

Microbix Announces Closing of Offering and Private Placement

Microbix Announces Closing of Offering and Private Placement

$6.9 Million of Gross Proceeds Received - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - MISSISSAUGA, May 19, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has closed its previously-announced bought-deal public offering (the “Offering”) and concurrent private placement (the “Placement”). The co-lead bookrunners and underwriters of the Offering, iA Private Wealth Inc. and  Bloom Burton Securities Inc. (the “Underwriters”), have purchased the full Offering,...

Microbix Reports Record Results for Q2 Fiscal 2021

Microbix Reports Record Results for Q2 Fiscal 2021

Record Q2 Sales of $4.35 million, Record Net Earnings of $0.8 million MISSISSAUGA, May 13, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2021 ending March 31, 2021 (“Q2” and “H1”), with record sales and earnings, plus progress upon its strategic goals. Management Discussion Q2 revenues were up 51% from 2020, achieving a record level of $4.35 million as Microbix continues to emphasize its sales of innovative, proprietary, and branded...

Microbix Announces Closing of Offering and Private Placement

Microbix Announces $6.0 Million of Financings

$5.0 Million Bought-Deal Public Offering and $1.0 Million Private Placement - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - MISSISSAUGA, April 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce it has entered into an agreement with iA Private Wealth Inc. and Bloom Burton Securities Inc. (the "Underwriters"), who will act as co-bookrunners and co-lead underwriters, pursuant to which the Underwriters have agreed to purchase, on a bought deal basis,...

Microbix & SpeeDx Form Exclusive Collaboration

Microbix & SpeeDx Form Exclusive Collaboration

Focus on Diagnostics and Controls for Anti-Microbial Resistant Infections MISSISSAUGA, CANADA and EVELEIGH, AUSTRALIA April 26, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and SpeeDx Pty. Ltd. (SpeedDx), a developer of innovative molecular diagnostics solutions, are pleased to announce the formation of a collaboration under which Microbix will be exclusive developer of Quality Assessment Products (QAPs™) to facilitate the registration and commercialization of SpeeDx diagnostic assays. The...

Microbix Receives $4.25 Million Order For Viral Transport Medium

Microbix Receives $4.25 Million Order For Viral Transport Medium

An Initial Order From Government Of Ontario Procurement Authorities MISSISSAUGA, April 23, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has received an initial order of CDN$ 4.25 million for its viral transport medium (generically known as “VTM” and branded as “DxTM™” by Microbix). DxTM is a test sample-collection device that is essential for PCR-testing for the virus causing COVID-19 disease. This initial order  has been made by a procurement authority representing the Province of...

Microbix to Present at Bloom Burton Investor Conference

Microbix to Present at Bloom Burton Investor Conference

Virtual Healthcare Investor Conference on April 20 & 21 MISSISSAUGA, April 19, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that its CEO, Cameron Groome, has been invited to present at the 2021 Bloom Burton & Co. Healthcare Investor Conference, being held virtually from Toronto, Ontario, Canada, on April 20 and 21, 2021. Microbix’s CEO will speak to its latest corporate presentation at 2:30 PM ET, on Wednesday, April 21 as a part of Track 3 of the Conference.  Microbix will also...

ONBOARDx™FLOQ® SARS-CoV-2 Variant Swab Kit / Verification Panel 20% off!

ONBOARDx™FLOQ® SARS-CoV-2 Variant Swab Kit / Verification Panel 20% off!

Confirm Your SARS Assay Is Not Confounded by SARS VOC Confirm your new Variant Test is Specific ONBOARDx Variant Kit Contains: ·     Variants of concern (VOC) and Wild Type (WT) whole SARS-CoV-2 genome ·     VOC genomes have all relevant mutations on multiple genes ·     UK B.1.1.7, South African B.1.351, Brazilian P.1 and WT ·     3 samples of each variant and WT, on Copan FLOQSwab® Convenient ONBOARDxTM Kits for instrument verification and operator training. Pre-order now. Shipping early May. First 500 orders received before April 23rd will receive a 20%...

Microbix Announces Annual and Special Meeting Voting Results

Microbix Announces Annual and Special Meeting Voting Results

MISSISSAUGA, March 31, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 30, 2021. At the Meeting, 43.29% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the Management Information Circular (the “Circular”)...

Virtual AGM on March 30, 2021

Virtual AGM on March 30, 2021

Once again, due to COVID -19 Pandemic, Microbix will be hosting a virtual AGM on March 30, 2021 at 1:00 pm.  The online link will allow shareholders to listen to the AGM and view a CEO presentation via Zoom.  Shareholders without up-to-date computer access can listen-in via telephone by using the teleconference numbers.  Details for these modes of remotely attending the AGM and for obtaining information in advance of the meeting are provided below: Click here for AGM Meeting Registration and Access Instructions Click here for INFO CIRCULAR Click here for PROXY...

Microbix & Seegene Canada Form COVID-Variant Collaboration

Microbix & Seegene Canada Form COVID-Variant Collaboration

Focus on Supporting Canadian Labs with Variant-related Assays and QAPs MISSISSAUGA & TORONTO, March 15, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene®), a  provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce   a collaboration under which Seegene will distribute and recommend Microbix’s new COVID-variant Quality Assessment Products (QAPs™) to  monitor the  workflow accuracy  of...

Microbix Antigen-test QAPs Now Available For Clinical Use

Microbix Antigen-test QAPs Now Available For Clinical Use

REDxFLOQ SARS-CoV-2 Antigen as IVD Controls in Canada, the EU, and the U.S. MISSISSAUGA, March 11, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability of more of its Quality Assessment Products (QAPs™) as In-Vitro Diagnostic “IVD” Controls – to monitor the workflow accuracy of antigen-based tests for the virus causing COVID-19 disease in Canada, the EU, and the United States. Antigen-based tests look for intact or fragmented virus within a patient sample, which can be taken and...

Why We Need To Test COVID-19 Tests

Why We Need To Test COVID-19 Tests

During the first peak of the coronavirus pandemic, it became apparent that the processing of the standard COVID-19 test using nasal swab samples, while considered a gold standard, was slow, taking over 24 hours to give results in most cases. As demand for quicker test results increased with supplies running low, scientists and engineers rushed to fill the gap at scale for rapid diagnostic testing that would replace the standard real-time reverse transcription polymerase chain reaction (rt-PCR) test. Such technologies included rapid antigen tests, antibody tests,...

Microbix Reports Record Results for Q2 Fiscal 2021

Microbix Announces Issuance of Stock Options

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, February 18, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with the CEO, CFO, and COO, Microbix’s Board of Directors has approved the issuance of...

Microbix Makes Early Repayment of 9% Interest Debenture

Microbix Announces Quality Products Distribution Agreement

Oneworld Accuracy as a Non-Exclusive Distributor for Africa and Other Territories MISSISSAUGA, February 16, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces an agreement (Agreement) with Oneworld Accuracy Inc. (1WA) to distribute Microbix’s Quality Assessment Products (QAPs™) on a non-exclusive basis across the continent of Africa, in Canada, and in the United States. Under the Agreement, 1WA will provide physical distribution, sales and marketing, and technical support for Microbix’s growing...

Microbix Announces Closing of Offering and Private Placement

Microbix Reports Results for Q1 Fiscal 2021

Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth MISSISSAUGA, February 11, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for the first quarter of its fiscal 2021, the three-months ended December 31, 2020 ("Q1"), with record sales and continued progress upon its strategic goals. Management Discussion Q1 results are demonstrating the diagnostics sector uptake of Microbix's innovative, proprietary, and branded test quality assessment products ("QAPs™"). Overall QAPs sales...

Microbix Announces Material First Sales of Viral Transport Medium

Microbix Announces Material First Sales of Viral Transport Medium

Initial Production of 50,000 Vials Entirely Sold MISSISSAUGA, February 9, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium (generically known as VTM and branded as DxTM™) that supports Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease. First sales of 50,000 vials (approximately one lot) have now been made to a private-market client at Microbix’s targeted pricing for this newly-available product. At the...

Microbix Receives $4.25 Million Order For Viral Transport Medium

Microbix Viral Transport Medium Now Available

Initial Capacity of 50,000 Vials/Week under Health Canada Regulation MISSISSAUGA, January 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the commercial availability of its viral transport medium (VTM) to support Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease. At the request of the Government of Ontario, Microbix has created a secure and locally-based supply of high-quality VTM, any shortage of which limits capacity for COVID-19 testing. Microbix...

Microbix & Copan Italia Execute Strategic Agreement

Microbix & Copan Italia Execute Strategic Agreement

For FLOQ devices & QAPs Co-branding, IP licensing, Co-marketing, Purchase, and Supply MISSISSAUGA, CANADA and BRESCIA, ITALY, December 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and Copan Italia S.p.A. (Copan®), the global leader in specimen collection technologies, announce their execution of a strategic agreement (Agreement) in relation to Microbix’s quality assessement products (QAPs™) and Copan’s flocked devices (FLOQ®). The Agreement between Microbix and Copan expands upon an existing...

Microbix Announces Closing of Offering and Private Placement

Microbix Reports Results for Fiscal 2020

Full-Year Sales of $10.5 Million, QAPs Sales Grow by 41%   MISSISSAUGA, December 18, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its 2020 fiscal year ("2020") and fourth quarter ("Q4") ended September 30, 2020, with continued progress toward its operational goals. Management Discussion 2020 did not achieve the financial targets we had set-out at the start of the year-...

Microbix & SpeeDx Form Exclusive Collaboration

Microbix Presenting Product Results at AACC

Reporting on Test-Workflow Controls for Important Sexually-Transmitted Infections MISSISSAUGA, CANADA, December 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has been invited to present about the performance of two types of its test-workflow Quality Assessment Products (QAPs™) at the 2020 virtual Scientific Meeting and Clinical Lab Expo of the American Association of Clinical Chemistry (AACC) taking place December 13-17, 2020. The first abstract presentation is titled “Novel...

Microbix Announces Addition to Board of Directors

Microbix Announces Addition to Board of Directors

Appointment of Anthony J. Giovinazzo, Accomplished Life Sciences Leader MISSISSAUGA, CANADA, December 7, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that Mr. Anthony J. Giovinazzo, an accomplished leader in the international life sciences industry, has joined its Board of Directors. Mr. Giovinazzo joined the Board of Directors effective today, and was also appointed as a member of the Audit Committee and the Human Resources, Compensation & Governance Committee. Mr. Giovinazzo has over...

Microbix Discloses New Products, Sales, And Capacity

Microbix Discloses New Products, Sales, And Capacity

Sales Of QAPs™ Kits To Help Qualify Multi-Pathogen Respiratory Test Systems MISSISSAUGA, CANADA, October 29, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability and initial material sales of “onboarding” kits of its quality assessment products (QAPs™), designed to help testing sites with the successful installation and qualification of multi-pathogen respiratory testing systems. Branded as “ONBOARDx™,” these QAPs kits are “RUO” classed and intended to assist labs with confirming...

Microbix Creates Further COVID-19 Quality Assessment Products

Microbix Creates Further COVID-19 Quality Assessment Products

QAPs™ To Support Accuracy Of COVID-19 Antigen-Test Workflows MISSISSAUGA, CANADA, October 20, 2020 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces its creation,  external verification, initial sales, and first shipments of a new class of quality assessment products (QAPs™) to help implement or ensure workflow accuracy of antigen-based tests for the virus causing COVID-19 disease. Antigen-based tests look for intact or fragmented virus within a patient sample, which can be taken and analyzed at the...

Ontario Helps Microbix Ensure Provincial COVID Testing Capacity

Ontario Helps Microbix Ensure Provincial COVID Testing Capacity

Grant Of $1.45 Million For Ontario-Based Production Of Critical Test Reagents MISSISSAUGA, October 13, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the execution of a grant agreement with the Ontario Together Fund (OTF) of the Ministry of Economic Development, Job Creation and Trade (MEDJCT). The Honorable Vic Fedeli, Minister of MEDJCT, Minister responsible for OTF, and Member of Provincial Parliament for Nipissing, has approved an OTF grant of $1.45 million to cover 50% of...

Microbix & Copan Italia Execute Strategic Agreement

Microbix Presenting COVID-19 Product Results To Industry

Abstract Reports Multi-Platform Utility Of IVD SARS CoV-2 Lab Workflow Control MISSISSAUGA, CANADA, September 22, 2020 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces it is has been invited to present about the performance of its COVID-19 in-vitro diagnostics (IVD) quality assessment products at “ECCVID,” a virtual conference on Coronavirus disease organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), taking place September 23-25, 2020. The...

Microbix Makes Early Repayment of 9% Interest Debenture

Microbix Announces Extension Of Warrant Expiry Dates

Applies For 12-Month Term Extension Of October 2015 And October 2017 Warrants MISSISSAUGA, CANADA, September 17, 2020 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces it has applied to the TSX to extend the term of an aggregate of 7,413,052 common share purchase warrants (“Warrants”) which were issued in connection with Microbix’s October, 2015 and October, 2017 private placement financings. The Warrants now entitle holders to purchase common shares of Microbix at prices from $0.36...

Microbix Announces Board Changes

Microbix Announces Board Changes

William J. Gastle Retiring, Martin Marino Nominated To Become Independent Chairman MISSISSAUGA, CANADA, September 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces that its founder and Executive Chairman William J. (Bill) Gastle has elected to retire effective October 15, 2020, and that Martin Marino has been nominated to become the Independent Chairman of its Board of Directors. Bill Gastle, a virologist by training, founded Microbix in 1984 and took it public in 1990. The...

Microbix’s REDx™ Controls Attain Australian TGA Registration

Microbix’s REDx™ Controls Attain Australian TGA Registration

Enables Use of COVID-19 and HPV Products by Australian Clinical Labs MISSISSAUGA, CANADA, September 10, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs™) – TGA registration of these REDx™ Controls & REDx™FLOQ® products by Microbix’s distributor, R-Biopharm, enables it to offer these workflow controls to Australian...

Microbix Announces Closing of Offering and Private Placement

Q3 Fiscal 2020

Year-Over-Year QAPs Sales Growth of 141% for Q3 MISSISSAUGA, August 14, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its third quarter and year to date fiscal 2020 (Q3 and YTD) ended June 30, 2020, with an increase of 141% in sales of Quality Assessment products (QAPs™). Management Discussion Overall, Q3 revenues were down from Q3 2019, due in part to negative pressure on antigen demand for non-COVID infectious disease testing. Specifically, lower antigen revenues were achieved...

Microbix AGM & Corporate Presentation – Spring 2020

Curious To See How We Perform A COVID Test?

Curious to see how we perform a COVID test? The video shows the laboratory steps involved in testing four patient samples along with one Control. The reagents and procedures are for the “CDC test” for SARS-CoV-2. Still, there is no difference in processing these patient samples from any sample evaluated for respiratory or sexually transmitted infections. The CDC test procedure is very similar to most manual molecular diagnostic tests. Most infectious disease tests are manual or semi-manual due to their low cost and versatility. These tests, like the CDC’s test,...

Microbix Shares Become Available For U.S. Investors

Microbix Shares Become Available For U.S. Investors

OTC Markets Listing and DTC Electronic Clearance Eligibility MISSISSAUGA, ON, CANADA, July 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces that it has completed two processes to make its common shares available for U.S. investors to buy and sell; (i) the listing of its common shares on the OTCQB platform under the ticker symbol MBXBF, and (ii) approval for electronic clearance and settlements of trades by way of DTC Eligibility. The OTCQX® Best Market, OTCQB® Venture...

2020 AGM Meeting Notice

2020 AGM Meeting Notice

Please note, due to the global circumstances, this year's Microbix Annual General Meeting will be held as a virtual meeting. Please stay tuned for link and instructions.

Hello world, a new COVID-19 EQA product!

Hello world, a new COVID-19 EQA product!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Microbix COVID-19 QAPs Attain EU “CE Mark” Registration

Microbix COVID-19 QAPs Attain EU “CE Mark” Registration

Enables Usage of SARS-CoV-2 Controls by Clinical Labs across Europe MISSISSAUGA, CANADA, June 5, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce the attainment of European Union “CE mark” (Conformité Européene) registration for its SARS-CoV-2 quality assessment products (QAPs™) – CE mark registration enables Microbix’s network of distributors that now covers 18 EU countries to immediately begin providing these products to clinical laboratories across the EU. The Microbix...

Microbix Announces Quality Products Distribution Agreement

Microbix Announces Quality Products Distribution Agreement

Appointment of Medical Supply Company of Ireland MISSISSAUGA, March 24, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®),  a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the appointment of The Medical Supply Company of Ireland (MSC) as a distributor. Under an agreement between the parties, MSC has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for the Republic of Ireland and Northern Ireland. As...

Microbix Engaged To Develop & Supply Custom QAPs™

Microbix Engaged To Develop & Supply Custom QAPs™

Instrument-Specific Controls to Support Rapid Tests for Viral Respiratory Pathogens MISSISSAUGA, June 1, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has been engaged to develop and supply custom quality assessment products (QAPs™) to support the registration and sales of a new point-of-care instrument and its tests for viral respiratory pathogens. Under an agreement between the parties, the companies’ technical teams are collaborating to develop custom QAPs to support submission...

Microbix Expanding QAPs™ Production Capacity

Microbix Expanding QAPs™ Production Capacity

Build-out to Support Tenfold Increase Now Underway MISSISSAUGA, CANADA, May 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has begun a build-out of its second facility that is initially intended to support a tenfold increase of production capacity for its QAPs™ quality assessment products – Which support the accuracy of clinical laboratory testing including, but not limited to, support for tests for the SARS-CoV-2 virus causing COVID-19 disease. Microbix’s current maximum QAPs...

Microbix Achieves Full Utilization Of Its Bioreactors

Microbix Achieves Full Utilization Of Its Bioreactors

Six Units in Ongoing Use for Foreseeable Future, Seventh Ordered MISSISSAUGA, CANADA, May 19, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has achieved full utilization of the six bioreactor units it installed for manufacturing the “antigens” which are at the core of immunoassays that establish exposure or immunity to the Rubella virus, the cause of German Measles. This marks a milestone for Microbix shareholders, as product from subsequent bioreactor batches will more fully...

Microbix Announces Quality Products Distribution Agreement

Microbix Announces Quality Products Distribution Agreement

Appointment of Labquality Oy of Finland for 7 Countries MISSISSAUGA, April 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Labquality Oy (Labquality) as a distributor of its Quality Assessment Products (QAPs™) in seven (7) countries. Under an agreement between the parties, Labquality has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Denmark, Estonia, Finland, Latvia, Lithuania, Poland, and Sweden. As distributor, Labquality will...

Microbix Reports Record Second Quarter Sales

Year-Over-Year Sales Growth of 28% in First-Half TORONTO, May 14, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its second quarter of fiscal 2018, the three-month period ending March 31, 2018 (“Q2”), with record sales and progress toward its operational goals. Second Quarter Financial Results Total Q2 revenue was $3,000,193, an increase of 13% compared to 2017 – on target with management’s goal of double-digit percentage sales growth. Revenues were dominated by antigen...

Microbix Shares Become Available For U.S. Investors

Microbix Reports Results For Q2 Fiscal 2020

Timing of Product Shipments Affects Results MISSISSAUGA, May 14, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2020 (“Q2” and “H1”) ended March 31, 2020, with the timing of product shipments to customers affecting Q2 results. Management Discussion Q2 revenues were down 32% from 2019, which had achieved record results for a fiscal second quarter. The year-over-year decline was largely due to the timing of customer orders and delivery...

Microbix Announces Quality Products Distribution Agreement

Microbix Announces Quality Products Distribution Agreement

Appointment of D.I.D. S.p.A. of Milan for Italy MISSISSAUGA, May 12, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Diagnostic International Distribution S.p.A. of Milan (D.I.D.) as distributor of its Quality Assessment Products (QAPs™) for Italy. Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Italy. As distributor, D.I.D. will provide marketing, inventorying, distribution, and...

Microbix COVID-19 QAPs Now Available for U.S. Labs

Registration Enables Immediate Usage of SARS-CoV-2 Controls by U.S. Clinical Labs MISSISSAUGA, CANADA, May 7, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce U.S. availability of its SARS-CoV-2 quality assessment products (QAPs™) –  FDA registration enabling immediate usage by U.S. clinical laboratories to evaluate performance, procedures, and workflow of tests that detect SARS-CoV-2 virus, the causative agent of COVID-19 disease. Cameron Groome, President and CEO, stated,...

Microbix Begins Providing COVID-19 Test Quality Products

Microbix Begins Providing COVID-19 Test Quality Products

SARS-CoV-2 Controls for Canadian Labs in Swab and Vial Formats MISSISSAUGA, CANADA, May 6, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has begun providing its REDx™FLOQ® SARS-CoV-2 swab-format and REDx™ SARS-CoV-2 vial format quality assessment products (QAPs™) as controls to clinical laboratories in Canada. A first commercial run of 4,000 units was split between the REDx™FLOQ® SARS-CoV-2 swab-format and REDx™ SARS CoV-2 vial-format, with positives and negatives of each format...

2020 AGM Meeting Notice

2020 AGM Meeting Notice

Please note, due to the global circumstances, this year's Microbix Annual General Meeting will be held as a virtual meeting. Please stay tuned for link and instructions.

Microbix Announces Quality Products Distribution Agreement

Microbix Announces Quality Products Distribution Agreement

Appointment of R-Biopharm AG for 11 Countries MISSISSAUGA, May 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of R-Biopharm AG (R-Biopharm) as distributor of its Quality Assessment Products (QAPs™) in eleven (11) countries. Under an agreement between the parties, R-Biopharm has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Australia, Belgium, Canada, France, Germany, Luxembourg, Netherlands, New Zealand, Norway, Spain, and the United...

Microbix Participating In COVID-19 Virtual Conference

Microbix Participating In COVID-19 Virtual Conference

Presentation and Panel Participation at Adelaide Capital Event on April 23 MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the “Virtual COVID & Healthcare Mini Conference” being hosted by Adelaide Capital on April 23 from 12:00-5:00 PM ET. The conference will showcase the contributions that Canadian companies are making to help fight the coronavirus pandemic. Microbix will be discussing its longstanding work in providing the...

Microbix Attains Health Canada Establishment Licensing

Microbix Attains Health Canada Establishment Licensing

Enables Immediate Usage of SARS-CoV-2 Controls by Clinical Labs across Canada MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator and exporter, announces that it has attained medical devices establishment licensing from Health Canada, enabling the immediate usage of its quality assessment products (QAPs™) by clinical laboratories, including its QAPs to help ensure the accuracy of COVID-19 disease testing. At present, Microbix has capacity to make 5,000 units per week of room-temperature stable COVID-19...

Hello world, a new COVID-19 EQA product!

Hello world, a new COVID-19 EQA product!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Welcome to WordPress. This is your first post. Edit or delete it, then start writing! Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Microbix Attains Health Canada Establishment Licensing

Microbix & Oneworld Create COVID-19 Test Quality Program

Laboratory External Quality Assessment, Proficiency Testing, & Accreditation MISSISSAUGA, ONTARIO and VANCOUVER, BC, CANADA, April 9, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®) and Oneworld Accuracy (1WA) announce a strategic collaboration to provide a global external quality assessment (EQA) program to support clinically-effective COVID-19 testing. Based in Canada, this program will be made available to all governments to underpin their public health responsibility to ensure accurate and reliable COVID-19 testing. In every country and more than...

Galen Weston’s Message To Canadians

Galen Weston’s Message To Canadians

Hi Everyone, Things continue to move fast and change quickly. Earlier today the Canadian Government announced they are restricting our international borders to limit the impact of COVID-19. As each of us try to understand how that will affect our daily lives, our friends, and our families, I wanted to reach out again. >> READ MORE

Microbix Announces Annual And Special Meeting Voting Results

Microbix Announces Annual And Special Meeting Voting Results

TORONTO, April 2, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the voting results from the Annual and Special Meeting of Shareholders (the “Meeting”) that was held on March 28, 2018. At the Meeting, 42.78% of the issued and outstanding shares were represented. A majority of shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the Management Information Circular (the “Circular”) dated February 9, 2018. The...

Microbix Creates Quality Assessment Product For COVID-19 Tests

Microbix Creates Quality Assessment Product For COVID-19 Tests

Whole-genome QMS Support Tool on COPAN® FLOQSwabs® MISSISSAUGA, CANADA, March 30, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®) announces the creation, verification, and imminent commercial availability of a quality assessment product (QAP™) to help ensure the accuracy of COVID-19 disease testing. By creating this unique product, Microbix is contributing to the development of new methods and improved methods for SARS-CoV-2 virus (COVID-19) detection and is helping to improve the accuracy of existing protocols by providing reliable, whole-genome...

Microbix Annual General Meeting Process Update

Microbix Annual General Meeting Process Update

Remote Access to the AGM Provided to Avoid Physical Attendance MISSISSAUGA, March 25, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, provides an update about its Annual General Meeting (“AGM”).   The AGM will still be held on March 31, 2020 at 1:00 pm, however due to the closure of our planned venue and alternative venues, we will be proceeding with access being provided online or via...

Microbix Announces Quality Products Distribution Agreement

Microbix Announces Quality Products Distribution Agreement

Appointment of Alpha-Tec Systems, Inc. for the United States MISSISSAUGA, June 4, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Alpha-Tec Systems, Inc. (Alpha-Tec), a Calibre Scientific Inc. firm, as distributor of its Quality Assessment Products (QAPs™) for the United States. Under an agreement between the parties, Alpha-Tec will provide physical distribution, sales and marketing, and technical support for the entire range of Microbix’s QAPs – including its whole-genome...

Microbix Announces Addition to Board of Directors

Microbix Announces Issuance Of Stock Options

Customer Validation of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces its first full-scale shipment of antigen produced using its new bioreactor manufacturing process, following customer validation. Microbix’ revenues are derived principally from the sales of its antigens for use in diagnostic tests. Historically, those antigens have been produced in thousands of “roller bottles,” a longstanding method of production that requires...

Microbix Reports Record Results for Q3 Fiscal 2021

Microbix Reports Results For Q1 Fiscal 2020

Positive Cash Flow from Operations Achieved MISSISSAUGA, February 13, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its first quarter of fiscal 2020 (“Q1”) ended December 31, 2019, with positive cash flow from operations (“CFO”) and seasonally weak sales. Management Discussion Microbix regularly has its weakest quarterly sales in its fiscal first quarters, due to their...

Annual General Meeting (AGM) – March 31st, 2020 UPDATE!

Annual General Meeting (AGM) – March 31st, 2020 UPDATE!

The AGM will still be held on March 31, 2020 at 1:00 pm, however due to the closure of our planned venue and alternative venues, we will be proceeding with access being provided online or via teleconference only. Due to the COVID-19 pandemic, Microbix also wants to avoid the need for in-person attendees at this year’s AGM, a goal enabled by setting-up an online link to allow shareholders to listen to the AGM and view a CEO presentation. Microbix will also provide a teleconference number, so that shareholders without up-to-date computer access can listen-in by...

Microbix Completes Non-Brokered Private Placement Of $2.3 Million

Microbix Completes Non-Brokered Private Placement Of $2.3 Million

TORONTO, October 19, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a brokered private placement financing totaling $2.33 million dollars, resulting in the issue of 7,784,500 million units (“Units”) at a price of $0.30 per unit. Each Unit consists of one common share (“Common Share”) of Microbix and one-half of one warrant to purchase one Common Share. Each whole warrant (“Warrant”) entitles the holder to purchase one additional Common...

Microbix Shares Become Available For U.S. Investors

Microbix Reports Results For Fiscal 2019

Full-Year Sales of $13.4 Million, Progress Toward Sustained Profitability MISSISSAUGA, December 20, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its fiscal year (“2019”) and fourth quarter (“Q4”) ended September 30, 2019, with stronger sales and progress toward its operational goals. Management Discussion In 2019, Microbix advanced upon its goal of sustained...

EUROGIN 2019

Microbix Invited To Present Product Results At HPV Congress

IVD Controls Data at EUROGIN, December 4-7, 2019 MISSISSAUGA, December 2, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces it has been invited to present the performance of its in-vitro diagnostics (IVD) quality products “IVD Controls” at EUROGIN 2019, the annual congress of the European Research Organization on Genital Infection & Neoplasia. At EUROGIN, Microbix will be...

Microbix Announces Addition to Board of Directors

Microbix Wins Ontario Business Award

2019 “OBAA” for Excellence in Export Strategy MISSISSAUGA, November 18, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices (QAPs™) that help ensure test accuracy, announces it has been awarded the “Beyond Borders” Ontario Business Achievement Award (OBAA) for 2019 by the Ontario Chamber of Commerce (OCC). The award was presented at the OCC OBAA gala the evening of November 14 and recognizes success in developing and...

Microbix Announces Addition to Board of Directors

Microbix Presenting At StableView TECH19 Conference

Meetings with Growth-Oriented Investors, October 3, 2019 MISSISSAUGA, October 1, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and quality control medical devices, announces that it will be presenting to investors about Microbix at the StableView TECH19 conference, organized by StableView Asset Management and being held at the Arcadian Court event venue in Toronto, ON, October 3, 2019. Microbix’s CEO, Cameron Groome, will make a corporate presentation and, with COO Ken Hughes and CFO Jim Currie, will...

Microbix Presenting At Muskoka Capital Conference

Microbix Presenting At Muskoka Capital Conference

Meetings with Growth-Oriented Investors, September 27-29, 2019 MISSISSAUGA, September 25, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and medical devices for test quality control, announces that it will be presenting to investors about Microbix at the Muskoka Capital Conference, organized by Capital Event Conferences and being held at the JW Marriott Rosseau Muskoka, in Minett, ON, September 27-29, 2019. Microbix’s CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company...

Microbix COVID-19 QAPs™ Now Available For U.S. Labs

Microbix Quality Products Enter U.S. Market

Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 19, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce U.S. availability of four innovative in-vitro diagnostic (IVD) control products for evaluating performance, procedures, and workflow of laboratory tests that detect and type HPV nucleic acids (DNA or RNA) in various human tissue samples. HPV is a family of more than 100 closely-related viruses, commonly described as “types,” of...

Microbix Quality Products Attain European Registration

Microbix Quality Products Attain European Registration

Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 5, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce European registration for four innovative in-vitro diagnostic (IVD) control products for evaluating performance, procedures, and workflow of laboratory tests that detect and type HPV nucleic acids (DNA or RNA) in various human tissue samples. HPV is a family of more than 100 closely-related viruses, commonly described as “types,”...

Microbix Shares Become Available For U.S. Investors

Microbix Reports Results For Q3 Fiscal 2019

Q3 Sales of $3.1 Million and $9.8 Million Year-To-Date TORONTO, August 12, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 (“Q3” & “YTD”), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals. Management Discussion Sales of $3.1 million for Q3 were down slightly vs. Q3 2018 and were to antigen customers...

Microbix Provides Bioreactor Update

Microbix Provides Bioreactor Update

Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order TORONTO, August 1, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on the conversion of its highest-selling product into bioreactors – that the largest customer for that antigen has confirmed its intended timetable for conversion of its future orders to bioreactor product and has provided its initial full-scale order. In 2018, Microbix completed a 500% expansion of its bioreactor capacity, moving to six...

Microbix Announces Quality Products Distribution Agreement

FedDev Ontario Supports New Microbix Facility In Mississauga

Contribution of $2.75 Million to Scale-up, Meet Demand, and Create Highly-Skilled Jobs MISSISSAUGA, July 30, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce the execution of a contribution agreement with the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). Today, the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, Minister responsible for FedDev Ontario, and Member of Parliament for Mississauga–Malton, announced a...

Microbix Announces Annual And Special Meeting Voting Results

Microbix Reports Results For Q2 Fiscal 2019

Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings TORONTO, May 13, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its second quarter and first half of fiscal 2019, the three-month and six-month periods ending March 31, 2019 (“Q2” & “H1”), with record sales, strong sales growth, improving percentage gross margin, materially positive net earnings, and progress on its strategic goals. Management Discussion Sales of $4.25 million for Q2 were very strong...

Microbix Will Be Exhibiting At The 35th Annual ASM Clinical Virology Symposium

Microbix Will Be Exhibiting At The 35th Annual ASM Clinical Virology Symposium

Microbix will be exhibiting at the 35th annual ASM/CVS (Clinical Virology Symposium) in Savannah on May 04-08th. We are showcasing our recently launched line of QAPs (Quality Assessment Products) used in a range of infectious disease diagnostics control applications. Featured products include the broadest line of HPV control products available today, along with a wide range of respiratory, STI, GI and other control materials, all based on our core competencies – growing viruses. Stop by our booth #927. Our mission is to support healthcare for humanity, and we...

Microbix Shares Become Available For U.S. Investors

Microbix To Present At Bloom Burton Conference

Healthcare Investment Conference in Toronto on May 2 & 3, 2018 TORONTO, April 30, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has been invited to present to investors about Microbix at the Bloom Burton & Co. Healthcare Investment Conference, being held at the Toronto Sheraton Centre Hotel on Wednesday and Thursday, May 2 and 3, 2018. Microbix’ CEO, Cameron Groome, will speak to its latest corporate presentation at 3:30 PM ET on Thursday, May 3, in Hall C of the conference....

Microbix Announces Quality Products Distribution Agreement

Microbix Announces Management Changes

Ken Hughes Appointed COO, Kathryn Froh Retiring TORONTO, April 18, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has appointed Dr. Kenneth (Ken) Hughes as its Chief Operating Officer (“COO”) and that Mrs. Kathryn Froh, its Vice President, Diagnostics is retiring from her full-time role, but will be remaining an employee and will be available to assist with special projects. Ken Hughes has been in the life sciences industry for more than 25 years and has worked as a CEO, senior...

Microbix Will Be Exhibiting At The 29th Annual ECCMID

Microbix Will Be Exhibiting At The 29th Annual ECCMID

Microbix will be exhibiting at the 29th annual ECCMID (European Congress of Clinical Microbiology and Infectious Disease) in Amsterdam on April 13-16th. We are showcasing our recently launched line of QAPs™ (Quality Assessment Products) used in a range of infectious disease diagnostics control applications. Featured products include the broadest line of HPV control products available today, along with a wide range of respiratory, STI, GI and other control materials, all based on our core competencies – growing viruses. Stop by our booth #1.5I. Our mission is to...

Microbix Participating In COVID-19 Virtual Conference

Annual General Meeting (AGM) – March 27th, 2019

Shareholders and other interested parties, please note Microbix will hold its annual general meeting (AGM) at the Toronto University Club located at 380 University Avenue, Toronto, M5G 1R6 on Wednesday March 27th at 1 PM. Click here for INFO CIRCULAR

Microbix Announces Addition to Board of Directors

Microbix Announces Issuance Of Stock Options

Using Shareholder-Approved Plan to Incentivize and Retain TORONTO, February 25, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In...

Microbix Shares Become Available For U.S. Investors

Microbix Reports Results For Q1 Fiscal 2019

Lower Sales, Improving Gross Margin, Positive Cash Flow from Operations TORONTO, February 12, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 (“Q1”), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals. Management Discussion Sales for Q1 were held back by a combination of delayed shipment of a viral antigen...

Microbix Provides Quality Assessment Products Update

Microbix Provides Quality Assessment Products Update

New Customers, More Products, and Expanding Capacity TORONTO, February 5, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on the expansion of its quality assessment product lines, announcing the addition of new customers, more products, and steps to expand its production capacity. Microbix’s quality assessment products (QAPs™) are stabilized and inactivated pathogen samples. QAPs are used by proficiency organizations, diagnostic test developers, researchers and clinical laboratories...

Microbix Enhances Quality Management System

Microbix Enhances Quality Management System

ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has attained the ISO 13485:2016 Medical Devices certification – an enhancement to its quality management system that is expected to accelerate the growth of its QAPs™ lines of quality assessment products. Microbix has operated under the ISO 9001:2015 general quality standard or its predecessors since 2009, manufacturing its antigen products under that system....

Microbix Announces Annual And Special Meeting Voting Results

Microbix Reports Results For Fiscal 2018

Full-Year Sales Growth of 23%, Progress Toward Sustained Profitability TORONTO, December 21, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its fourth quarter of fiscal 2018, the three-month period ending September 30, 2018 (“Q4”), with strong sales and progress toward its operational goals. Management Discussion In 2018, Microbix advanced upon its goal of sustained profitability, tripling its prior rate of sales growth, increasing its manufacturing capacity, and undertaking...

Microbix Wins Business Award Of Excellence

Microbix Wins Business Award Of Excellence

Recognized with 2018 Business Innovation Award by MBOT TORONTO, November 19, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has been recognized with the 2018 Business Innovation Award by the Mississauga Board of Trade (MBOT). The award was provided to Microbix at the MBOT Business Awards of Excellence event the evening of November 15. The 2018 Business Innovation Award was in recognition of Microbix’s innovations in making native antigens and quality assessment products, its...

Microbix Exhibiting At MEDICA Trade Fair

Microbix Exhibiting At MEDICA Trade Fair

Showcasing Antigen and Quality Assessment Products TORONTO, November 6, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its antigens and quality assessment products at MEDICA, a leading international trade fair for the medical sector. The 2018 MEDICA fair is being held at the Messe Dusseldorf exhibition grounds in Dusseldorf, Germany from November 12 to 15, 2018. At MEDICA, Microbix will showcase its industry-leading line of native antigen products and its new...

Microbix Presenting At Muskoka Capital Conference

Microbix To Present At Muskoka Capital Conference

Conference Introduces Growth Companies to Investors, September 28-30, 2018 TORONTO, September 27, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be presenting to investors about Microbix at the Muskoka Capital Conference, organized by Capital Event Conferences and being held at the JW Marriott Rosseau Muskoka, in Minett, Ontario from September 28-30, 2018. Microbix’ CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the...

Microbix Announces Annual And Special Meeting Voting Results

Microbix Reports Record Third Quarter Sales

Microbix Reports Record Third Quarter Sales Year-Over-Year Sales Growth of 24% in First Nine Months   TORONTO, August 14, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its third quarter of fiscal 2018, the three-month period ending June 30, 2018 (“Q3”), with record sales and progress toward its operational goals. Third Quarter Financial Results Total Q3 revenue was $3,235,224, a 17% increase over 2017 third quarter revenue of $2,773,365.  Included were antigen and...

Microbix Exhibiting At AACC Exposition

Microbix Exhibiting At AACC Exposition

Showcasing New Quality Assessment Products TORONTO, July 26, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its Quality Assessment Products (QAPs™) at the 70th annual clinical laboratory exposition of the American Association of Clinical Chemistry (AACC). The 2018 AACC exposition is being held at the McCormick Place convention center in Chicago, Illinois from July 31 to August 2, 2018. Microbix will be showcasing a series of its new PROCEEDx™ brand QAP products at...

Microbix to Present at Bloom Burton Investor Conference

Microbix To Present At Okanagan Capital Conference

Conference Introduces Growth Companies to Investors, July 12-14, 2018 TORONTO, July 12, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be presenting to investors about Microbix at the Okanagan Capital Conference, organized by Capital Event Conferences and being held at the Delta Grand Okanagan hotel in Kelowna, B.C. from July 12 to 14, 2018. Microbix’ CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of...

Microbix Expanding QAPs™ Production Capacity

Microbix Completes Multiple Facility Upgrades

Production Capacity Increased to Support Growth Objectives TORONTO, May 8, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the completion of multiple upgrades to its production facility, to improve its revenue capacity and in support of corporate growth objectives. About Microbix’ Antigens & Quality Products Business Microbix is a leading independent producer of bacterial and viral antigens for use in medical diagnostics and laboratory quality assessment processes, selling over 100...

Microbix Participating In COVID-19 Virtual Conference

Microbix To Present At Bloom Burton Conference

Healthcare Investor Conference in Toronto on April 30 & May 1 TORONTO, April 29, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that its CEO, Cameron Groome, has been invited to present at the 2019 Bloom Burton & Co. Healthcare Investment Conference, being held at the Metro Toronto Convention Centre on April 30 and May 1. Microbix’ CEO will speak to its latest corporate presentation at 4:00 PM ET, on Tuesday, April 30 at the Metro Convention Centre, Conference Hall B.  Microbix’...

Microbix Engages Drug Licensing Advisor

Microbix Engages Drug Licensing Advisor

Torreya Partners to Assist with Kinlytic® urokinase TORONTO, April 26, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the engagement of Torreya Partners LLC of New York to assist it in reaching an agreement that enables the re-launch of its clot-buster drug, Kinlytic® urokinase,  into the United States market. About Kinlytic® urokinase Kinlyic® urokinase (formerly Abbokinase®) is an injectable thrombolytic or “clot-buster.” The drug is approved in the U.S. and Canada to clear blood clots and...

ECCMID Madrid, Spain April 21-24

ECCMID Madrid, Spain April 21-24

Join us at ECCMID in Madrid in April. It will be our first time exhibiting there and our QAPs™ lines will be our highlighted. For more information, visit http://www.eccmid.org/

Microbix Announces Annual And Special Meeting Voting Results

Microbix Reports Record First Quarter Sales – Year-Over-Year Sales Growth Of 48%

TORONTO, February 14, 2018 ‐ Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its first quarter of fiscal 2018, the three‐ month period ending December 31, 2017 (“Q1”), with record sales and improving margins and earnings. First Quarter Financial Results Total Q1 revenue was $2,885,567, an increase of 48% compared to the first quarter of fiscal 2017. Normalized to remove approximately $600,000 of revenues intended for Q4 that were delayed into Q1, year‐over‐year sales growth was...

Microbix Featured At Cantech Investment Conference

Microbix Featured At Cantech Investment Conference

Invited onto Panel about Managing Canadian Healthcare Companies for Growth TORONTO, January 29, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces its participation as a panelist and exhibitor at the Cantech Investment Conference, being held at the Metro Toronto Convention Centre on January 31, 2018. Celebrating its fifth anniversary, Cantech is Canada’s largest technology investment conference. Cantech works to connect approximately 3,500 engaged investors with over 100 leading...

Microbix Featured At Cantech Investment Conference

Cantech Investor Conference

JANUARY 29, 2018 Celebrating the 5th anniversary of Canada’s largest technology investment conference. We are excited to bring over 3500 engaged investors together with 100+ leading technology companies. Visit us at the Metro Toronto Convention Center on January 31 from 8 AM to 7 PM For more information, http://cambridgehouse.com/e/cantech-investment-conference-2018-72

Microbix Expands Quality Assessment Product Family

Microbix Expands Quality Assessment Product Family

  48 New Products Being Added, Under PTDx™ and PROCEEDx™ Brands TORONTO, January 18, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the expansion of its quality assessment product family, with 48 new products being completed and made available for sale under its PTDx™ and PROCEEDx™ brands. Microbix’ quality assessment products are used by clinical laboratories, diagnostic test developers, researchers and proficiency organizations. Microbix has long offered a range of such products to...

Microbix Reports Full Year And Fourth Quarter Results – Record Sales Of $10.2 Million Achieved For Fiscal 2017

Microbix Reports Full Year And Fourth Quarter Results – Record Sales Of $10.2 Million Achieved For Fiscal 2017

TORONTO, December 21, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, reports financial results for its fiscal year and fourth quarter ended 30 September, 2017 (“2017” and “Q4”). Management Discussion In 2017, the Company achieved a number of notable milestones, including attaining record sales of over $10 million. Operational achievements included renewing and expanding agreements with key customers, validating the production of our highest-grossing product in a new, efficient bioreactor production platform,...

Microbix Confirms Ramp-Up Of Production – Bioreactor Capacity Increasing By 500%

Microbix Confirms Ramp-Up Of Production – Bioreactor Capacity Increasing By 500%

TORONTO, November 27, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, confirms its production ramp-up, with a 500% increase in bioreactor capacity and other processing upgrades. Microbix’ revenues are mainly from sales of its antigens as critical components for makers of tests that diagnose infectious diseases. Antigens are traditionally produced in thousands of “roller bottles,” a method requiring considerable space, material and labour. Instead and in a significant advancement, Microbix has...

Microbix Completes Second Tranche Of Brokered Private Placement Tranche Gross Proceeds Of $1,164,640, Total Proceeds Of $3,500,000

Microbix Completes Second Tranche Of Brokered Private Placement Tranche Gross Proceeds Of $1,164,640, Total Proceeds Of $3,500,000

TORONTO, October 27, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a second and final tranche of the brokered private placement financing announced on October 19, 2017. An aggregate of 7,784,500 Units were issued in the first tranche for gross proceeds of $2.33 million. Microbix has now closed a second tranche of private placement financing for further gross proceeds of $1.17 million, resulting in the issue of 3,882,133 more Units at a...

Microbix Completes Brokered Private Placement – Gross Proceeds Of $2.3 Million

Microbix Completes Brokered Private Placement – Gross Proceeds Of $2.3 Million

TORONTO, October 19, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a brokered private placement financing totaling $2.33 million dollars, resulting in the issue of 7,784,500 million units (“Units”) at a price of $0.30 per unit. Each Unit consists of one common share (“Common Share”) of Microbix and one-half of one warrant to purchase one Common Share. Each whole warrant (“Warrant”) entitles the holder to purchase one additional Common...

Microbix Announces End Of Legal Dispute – Allegations By ZeptoMetrix Withdrawn

Microbix Announces End Of Legal Dispute – Allegations By ZeptoMetrix Withdrawn

OCTOBER 11, 2017 TORONTO, October 11, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, is pleased to announce the withdrawal of legal claims alleging patent infringement that were filed in Canadian Federal Court against Microbix by ZeptoMetrix Corporation in October, 2016. The allegations by ZeptoMetrix have been withdrawn, following a settlement reached by the two companies. The withdrawal of the lawsuit is “with prejudice,” meaning that these allegations cannot be reasserted in Federal Court by ZeptoMetrix in...

Microbix Provides Bioreactor Update

Microbix Announces First Shipment Of Bioreactor Antigen

Customer Validation Of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces its first full-scale shipment of antigen produced using its new bioreactor manufacturing process, following customer validation. Microbix’ revenues are derived principally from the sales of its antigens for use in diagnostic tests. Historically, those antigens have been produced in thousands of “roller bottles,” a longstanding method of production that requires...

Microbix Reports Record Results for Q2 Fiscal 2021

Microbix To Amend Share Purchase Warrant Terms

TORONTO August 24 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces it has applied to the TSX to amend the terms of 1,500,000 common share purchase warrants (the “Warrants”) issued in connection with a non-brokered private placement and held by one of its independent directors. The Warrants were issued in relation to a non-brokered private placement of units comprised of one common share and a common share purchase warrant, completed on August 21, 2014. Each Warrant currently entitles the...

Microbix Poster Covering SARS-CoV-2 Variants of Concern (VOC) QAPs at AACC 2021

Microbix Reports Record Third Quarter & Nine Month Sales – Year-Over-Year Sales Growth Exceeding 20%

TORONTO, August 14, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reports financial results for its fiscal third quarter and nine months ended June 30, 2017 (“Q3” and “9 Mo.”). Third Quarter Financial Results Total Q3 revenue was $2,773,365, an increase of 23% compared to the same quarter of fiscal 2016. Most revenues were derived from sales of antigen products, which are principally used in the manufacture of diagnostic tests for infectious diseases. Growth was driven by increased antigen orders from...